Abstract
Metastatic breast cancer (BC) to the cervix is relatively rare among women with BC. Although the most common histopathological type of BC is invasive ductal carcinoma, invasive lobular carcinoma is more likely to metastasize to the female reproductive system due to its characteristic of the loss of E-cadherin. BC patients with metastasis to the cervix often exhibit no obvious clinical symptoms or may present with cervical-related symptoms, making early diagnosis challenging. CDK4/6 inhibitors, when combined with either aromatase inhibitors or fulvestrant, can enhance the prognosis for both premenopausal and postmenopausal women with recurrent ER-positive BC. We reported a patient with cervical metastasis of BC, who was ER-positive and HER2-negative. The patient received treatment with fulvestrant and abemaciclib after surgery for metastatic cervical cancer, achieving a progression-free survival of 31 months. We hope this case report will encourage more clinicians to prioritize gynecological examinations for patients with BC, particularly cervical cancer screening, in order to enhance the quality of life and prognosis for these individuals.